Ulcerative colitis is an idiopathic
inflammatory bowel disease characterized by intestinal
inflammation; blocking this inflammatory process may be the key to the development of new naturally occurring anti-inflammatory drugs, with greater efficiency and lower side effects. The objective of this study is to explore the effects of
bergenin (BG) in TNBS (2,4,6-trinitrobenzenesulfonic acid)-induced acute
colitis model in rats in order to assist in the studies for the development of novel
natural product therapies for
inflammatory bowel disease. 48 Wistar rats were randomized into six groups: (i) Control and (ii) TNBS control; (iii) 5-ASA 100 mg/kg/day (iv) BG 12 mg/kg/day (v) BG 25 mg/kg/day and (vi) BG 50 mg/kg/day.
Colitis was induced by instillation of TNBS.
Colitis was evaluated by an independent observer who was blinded to the treatment. Our results revealed that
bergenin decreased the macroscopic and microscopic damage signs of
colitis, and reduced the degree of neutrophilic infiltration in the colon tissue; also, it was capable to down-regulate COX-2, iNOS, IkB-α, and pSTAT3
protein expression. Similarly, using a protocol for indirect ELISA quantification of
cytokines,
bergenin treatment reduced IL-1β, IFN-γ and
IL-10 levels, and inhibited both canonical (IL-1) and non-canonical (IL-11) NLRP3/ASC
inflammasome signaling pathways in TNBS-induced acute
colitis. Conclusion: Our study has provided evidence that administration of
bergenin reduced the damage caused by TNBS in an experimental model of acute
colitis in rats, reduced levels of pro-inflammatory
proteins and
cytokines probably by modulation of pSTAT3 and NF-κB signaling and blocking canonical and non-canonical NLRP3/ASC
inflammasome pathways.